We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,415

CIALIS Patent Survives Validity Challenge on Appeal
  • McCarthy Tétrault LLP
  • Canada
  • May 19 2016

Last year we wrote about a trilogy of Federal Court decisions relating to Eli Lilly’s erectile dysfunction (ED) drug CIALIS (tadalafil). While Lilly


Allergan fails to demonstrate to FC that Apotex’s allegations of invalidity are not justified
  • PCK Perry + Currier Inc Currier + Kao LLP
  • Canada
  • June 6 2017

Not adequately distinguishing between mere goals and promises of utility in the claims of a patent could spell out disaster for patentees. In this


International Trade Compliance Update - September 2016
  • Baker McKenzie
  • United Kingdom, USA, Australia, Canada, European Union
  • September 7 2016

On 19 August 2016, the Russian Federation notified the WTO that it intends to initiate negotiations pursuant to Paragraph 1143 of the Working Party


December 2016 International Trade Compliance
  • Baker McKenzie
  • Australia, Canada, European Union, Global, OECD, United Kingdom, USA
  • December 12 2016

On 29 November 2016, the WTO reported that most WTO members welcomed Ecuador’s efforts to lower its import surcharge rates and reduce the number of


Federal Court Reissues its Original Decision to Award Section 8 Damages After the Federal Court of Appeal Held the Original Decision Relied on Inadmissible Hearsay Evidence
  • Borden Ladner Gervais LLP
  • Canada
  • June 7 2017

The Federal Court has reaffirmed and reissued its original decision awarding section 8 damages to Teva following a redetermination that was ordered by


Biosimilars in Canada: at a tipping point
  • Osler Hoskin & Harcourt LLP
  • Canada
  • May 24 2016

Biosimilars, or highly similar versions of innovative biologic medicines, have now been approved and marketed in developed countries for several


Apotex's claims against current and former Ministers and civil servants working at the Ministry of Health is not struck for a lack of jurisdiction
  • Borden Ladner Gervais LLP
  • Canada
  • May 31 2017

The Federal Court has refused to strike a claim brought by Apotex against current and former ministers and civil servants working at the Ministry of


Motion to Amend Dismissed in Respect of the Contested Amendments
  • Borden Ladner Gervais LLP
  • Canada
  • June 7 2017

The Court dismissed the Plaintiffs by Counterclaim's motion to amend their statement of defence and counterclaim in respect of the contested


Dentons' pick of global regulatory trends to watch in 2017
  • Dentons
  • Australia, Canada, China, European Union, Germany, Mexico, OECD, United Kingdom, USA
  • February 9 2017

Dentons’ team of regulatory lawyers from key jurisdictions around the world weigh in on regulatory trends to watch in 2017 in the US, Europe, the UK


Cialis Canadian Patent Knocks Out Double Patenting Challenge
  • Bereskin & Parr LLP
  • Canada
  • January 20 2017

Eli Lilly's Canadian patent on treatment of erectile dysfunction with Cialis continues to defy all challengers. A recent appeal case originated from